Insilico Medicine nominates AI-designed ISM9077 for eye diseases, partners with THPharma on THP-001

Aug 10, 2026 · Issue 2 · 5 sources, 5 articles

Insilico Medicine nominated its AI-designed ISM9077 for dry AMD, uveitis and dry eye disease. The company is launching a reverse-translation drug discovery collaboration with THPharma around the phase 3 candidate THP-001 (August 10–13).

Who is affected and how

pharmaceuticals

Insilico's case illustrates a strategy that uses AI from target nomination through to rethinking assets at phase 3.

Sources

• Insilico Medicine nominates AI-designed ISM9077 for dry AMD, uveitis and dry eye disease | Drug Target Reviewdrugtargetreview.com · Aug 10, 2026
• How Insilico Medicine Uses AI to Speed Up Drug Discoverybiotecnika.org · Aug 13, 2026
• Insilico Medicine and THPharma Launch AI Research Collaboration to Build 'Reverse Translation' Drug Discovery Strategy Around Phase 3 Candidate THP-001 - Insight, China's Pharmaceutical Industryflcube.com · Aug 13, 2026
• How China's AI Drug Discovery Is Reshaping Pharmaceutical R&D | AiBlendTechaiblendtech.com · Aug 15, 2026
• Research and Innovation: How AI Is Rewriting the Rules of Drug Discoveryphilipropaynephd.substack.com · Aug 16, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.